Richard Law Analyst PerformanceAnalyst at The Goldman Sachs GroupRichard Law is a stock analyst at The Goldman Sachs Group in the medical sector, covering 13 publicly traded companies. Over the past year, Richard Law has issued 25 stock ratings, including buy, hold, and sell recommendations. While full access to Richard Law's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Richard Law's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings30 Last 1 YearsBuy Recommendations50.00% 15 Buy RatingsCompanies Covered13 Unique Companies Ratings Distribution30RatingsDistribution of strong buy, buy, hold, and sell ratings by Richard Law.RatingPercentageCount Strong Buy0.0%0 ratings Buy50.0%15 ratings Hold40.0%12 ratings Sell10.0%3 ratingsOut of 30 total stock ratings issued by Richard Law at The Goldman Sachs Group, the majority (50.0%) have been Buy recommendations, followed by 40.0% Hold and 10.0% Sell.Best & Worst CallsBest Call0000.0%MLYSFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%MLTXJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ13 companiesRichard Law, an analyst at The Goldman Sachs Group, currently covers 13 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical13 companies100.0%Richard Law of The Goldman Sachs Group specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE11 companies84.6%MED - DRUGS2 companies15.4% Richard Law's Ratings History at The Goldman Sachs Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsVRDNViridian Therapeutics4/7/2026Lower Price Target$14.06$31.00Buy$0.0000.00% ROIVRDNViridian Therapeutics3/31/2026Lower Price Target$19.75$36.00Buy$0.0000.00% ROIBCAXBicara Therapeutics3/31/2026Boost Price Target$19.46$16.00Neutral$0.0000.00% ROIOLMAOlema Pharmaceuticals3/18/2026Lower Price Target$15.06$27.00Buy$0.0000.00% ROIPTGXProtagonist Therapeutics3/3/2026Boost Price Target$91.56$95.00Neutral$0.0000.00% ROIRCKTRocket Pharmaceuticals3/2/2026Boost Price Target$4.91$3.00Sell$0.0000.00% ROICLDXCelldex Therapeutics3/2/2026Boost Price Target$30.13$34.00Neutral$0.0000.00% ROIMLTXMoonLake Immunotherapeutics1/14/2026Downgrade$17.41$10.00Sell$0.0000.00% ROICRNXCrinetics Pharmaceuticals1/12/2026Upgrade$53.25$67.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals12/11/2025Boost Price Target$32.94$38.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. OLMAOlema Pharmaceuticals11/21/2025Boost Price Target$21.40$26.00Buy$0.0000.00% ROINUVLNuvalent11/18/2025Boost Price Target$105.26$135.00Buy$0.0000.00% ROIVRDNViridian Therapeutics11/6/2025Reiterated Rating$27.89$40.00Buy$0.0000.00% ROIARQTArcutis Biotherapeutics10/30/2025Boost Price Target$25.64$29.00Neutral$0.0000.00% ROIMLTXMoonLake Immunotherapeutics10/1/2025Reiterated Rating$6.98$7.00Neutral$0.0000.00% ROIMLTXMoonLake Immunotherapeutics9/30/2025Downgrade$7.17$7.00Neutral$0.0000.00% ROICRNXCrinetics Pharmaceuticals9/26/2025Boost Price Target$45.58$40.00Neutral$0.0000.00% ROIMLYSMineralys Therapeutics9/9/2025Boost Price Target$37.15$52.00Buy$0.0000.00% ROIVRDNViridian Therapeutics8/7/2025Boost Price Target$16.57$30.00Buy$0.0000.00% ROIMLTXMoonLake Immunotherapeutics8/6/2025Boost Price Target$52.25$82.00Buy$0.0000.00% ROIARQTArcutis Biotherapeutics7/25/2025Initiated Coverage$15.02$18.00Neutral$0.0000.00% ROIOLMAOlema Pharmaceuticals5/14/2025Lower Price Target$4.20$18.00Buy$0.0000.00% ROIRCKTRocket Pharmaceuticals5/9/2025Lower Price Target$7.00$13.00Neutral$0.0000.00% ROICLDXCelldex Therapeutics5/9/2025Lower Price Target$18.54$31.00Neutral$0.0000.00% ROIVRDNViridian Therapeutics5/7/2025Lower Price Target$12.30$27.00Buy$0.0000.00% ROIVKTXViking Therapeutics4/8/2025Initiated Coverage$21.52$30.00Neutral$00.0000.00% ROIRCKTRocket Pharmaceuticals3/3/2025Lower Price Target$9.15$15.00Neutral$0.0000.00% ROIMLYSMineralys Therapeutics2/13/2025Lower Price Target$10.36$24.00Buy$00.0000.00% ROISLNSilence Therapeutics2/11/2025Initiated Coverage$4.92$6.00Sell$0.0000.00% ROIMLTXMoonLake Immunotherapeutics1/17/2025Upgrade$41.47$82.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyRoyal Bank Of CanadaBerenberg BankUBS GroupCitigroupBarclaysWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
